Tower Research Capital LLC (Trc) 89bio, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in 89bio, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,593 shares of ETNB stock, worth $46,589. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,593
Previous 23,226
75.92%
Holding current value
$46,589
Previous $186,000
77.96%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$126 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$118 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$66.6 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$61.5 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$58.4 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $387M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...